OTC/Rx Sodium Phosphate Laxative Claim Dispute Referred By NAD
This article was originally published in The Tan Sheet
InKline Pharmaceuticals, which sells Rx sodium phosphate tablets, has declined to participate in the NAD self-regulatory forum, maintaining NAD is not the proper authority to review its marketing claims
You may also be interested in...
A DTC radio ad for Aventis' Rx antihistamine Allegra (fexofenadine) misrepresents state laws concerning driving impairment when referring to Pfizer/Warner-Lambert Consumer Group's Benadryl, the firm alleges in a case to appear in an upcoming NAD Case Reports
DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC